UNSPSC 51141544: Decimemide

This classification denotes an anticonvulsant agent with the molecular formula C19H31NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GAF9GJ18J5, chemically known as 4-n-decyloxy-3,5-dimethoxybenzoic acid amide but generally known as decimemide, which bears US NIH Compound Identifier 26929. European Medicines Agency schedules Decimemide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06931MIG.

UNSPSC 51141544 Decimemide, a Commodity code, encompasses pharmaceutical products and related health interventions that state and local governments procure for community health, emergency response, and medication management programs. Recent state and local solicitations under this code reflect purchases of naloxone (opioid overdose reversal medication), safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products distributed through established supply chains. State health and human services agencies, county health departments, and cooperative purchasing alliances (notably the Minnesota Multistate Cooperative Purchasing Alliance) are the primary issuing bodies. Work solicited includes competitive bidding for emergency-response medications with quarterly delivery schedules, exploratory market research on direct-to-manufacturer prescription programs, and large-scale RFPs for generic pharmaceutical catalogs with specific compliance requirements including cGMP certification, Drug Supply Chain Security Act adherence, and FDA approval.

Activity under the code spans multiple states, with recent solicitations from Florida (Seminole County), Texas (Health and Human Services Commission), and Minnesota (MMCAP, serving multiple participating states including Oregon). The most visible recent opportunity is Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, requiring quarterly deliveries to the county community health building with all shipping included in pricing. Minnesota's MMCAP RFP S1070000015802, posted January 20, 2026 with a March 26, 2026 response deadline, establishes multiple contracts for generic pharmaceuticals and OTC products across state and local facilities, requiring vendors to work through three authorized wholesalers and demonstrating the scale of cooperative purchasing models in pharmaceutical procurement. Texas HHS's RFI HHS0017013, posted April 3, 2026, signals exploratory activity around direct-to-manufacturer prescription programs but does not yet represent a formal competitive solicitation.